Related Experiment Video
Updated: Jul 1, 2025
11:28
A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically
Published on: September 9, 2015
29.0K
Dalbavancin Sequential Therapy for Gram-Positive Bloodstream Infection: A Multicenter Observational Study
Nicholas Rebold1,2,3, Sara Alosaimy4,5, Jeffrey C Pearson6
1Wayne State University, Detroit, MI, USA. nicholas.rebold@howard.edu.
Infectious Diseases and Therapy
|March 1, 2024
Summary
Dalbavancin is effective for treating Gram-positive bloodstream infections (BSI), especially for patients needing early discharge. This real-world study shows low failure rates, supporting its use as sequential therapy.
Area of Science:
- Infectious Diseases
- Pharmacology
- Clinical Medicine
Background:
- Long-acting lipoglycopeptides like dalbavancin offer potential for Gram-positive bloodstream infections (BSI).
- Dalbavancin may be beneficial for patients facing discharge barriers or requiring extended antibiotic treatment.
Purpose of the Study:
- To evaluate dalbavancin as sequential therapy for Gram-positive BSI.
- To provide multicenter, real-world evidence on dalbavancin's effectiveness and safety.
Main Methods:
- Retrospective cohort study across 13 US centers (July 2015-July 2021).
- Included 115 patients with Gram-positive BSI treated with dalbavancin.
- Analyzed clinical failure, mortality, and recurrence rates.
Main Results:
- The study included 115 patients with a mean age of 48.5 years; 54% were male, and 40% were drug users.
- Staphylococcus aureus was the most common pathogen (72%).
- Composite clinical failure was 12.2%, 90-day mortality was 7.0%, and 90-day BSI recurrence was 3.5%.
Conclusions:
- Dalbavancin shows promise for facilitating hospital discharge in Gram-positive BSI cases.
- Further randomized controlled trials are needed to confirm dalbavancin's role against current standards.
